Thalidomide approval brings tight restrictions on access.
D017277:Drug Approval / Q000331:legislation & jurisprudence; D016903:Drug Monitoring; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D007917:Leprostatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D010353:Patient Education as Topic; D018579:Patient Selection; D013792:Thalidomide / Q000008:administration & dosage* / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
D007166:Immunosuppressive Agents; D007917:Leprostatic Agents; D013792:Thalidomide